Macular degeneration is not curable. No treatment available today can reverse the disease or fully restore vision that has already been lost. But that headline fact doesn’t capture the full picture: treatments can slow progression significantly, and for the wet form of the disease, injections into the eye can stabilize or even partially improve vision in many patients. Roughly 8 million people worldwide currently live with vision impairment from age-related macular degeneration (AMD), a number projected to reach 21 million by 2050.
Why a Cure Is So Difficult
AMD damages the macula, a tiny area at the center of the retina responsible for sharp, detailed vision. The disease comes in two forms. Dry AMD, which accounts for about 80 to 90 percent of cases, involves a gradual thinning of retinal cells. Wet AMD occurs when abnormal blood vessels grow beneath the retina and leak fluid or blood, causing faster and more severe vision loss.
The core challenge is that once retinal cells die, the body cannot regenerate them. Treatments can protect surviving cells or slow the rate of damage, but they cannot rebuild what’s already gone. This is why early detection matters so much: the sooner treatment begins, the more functional vision you can preserve.
Treating Wet AMD With Eye Injections
Wet AMD has the most effective treatment options. Drugs that block a protein called VEGF (which fuels the growth of abnormal blood vessels) are injected directly into the eye on a regular schedule. These injections can stop new vessel growth and reduce fluid leakage. In the short term, many patients see measurable vision improvement within weeks of starting treatment.
Long-term results are more nuanced. A 10-year study of patients receiving these injections found that 63 percent maintained functional vision, losing fewer than 15 letters on an eye chart over the full decade. Nearly 58 percent kept vision above a threshold considered adequate for daily tasks. However, vision did decline gradually over time, with an average loss of about 11 letters across the 10-year period. The injections don’t stop the disease entirely; they manage it, much like blood pressure medication manages hypertension without curing it.
Treatment typically requires injections every month or every other month, sometimes for years. The frequency can be adjusted based on how your eye responds, but most people need ongoing treatment to maintain the benefit.
New Options for Advanced Dry AMD
For most of its history, dry AMD had no approved treatment at all. That changed in 2023, when two drugs became available for geographic atrophy, the advanced stage of dry AMD where patches of retinal cells die off completely.
Both drugs work by calming part of the immune system’s inflammatory response that contributes to cell death. They require injections into the eye monthly or every other month, similar to wet AMD treatment. In clinical trials lasting one year, these drugs slowed the expansion of geographic atrophy by about 14 to 20 percent. That’s a meaningful reduction in the rate of damage, but neither drug improves eyesight or restores lost vision. They slow the disease down; they don’t stop it.
Slowing Early Dry AMD With Supplements
If you have early or intermediate dry AMD, a specific vitamin formula known as AREDS2 can reduce the risk of progressing to advanced disease. The formula contains 500 mg of vitamin C, 400 IU of vitamin E, 80 mg of zinc, 2 mg of copper, 10 mg of lutein, and 2 mg of zeaxanthin. These supplements are widely available over the counter, and many eye doctors recommend them as a standard part of managing early AMD.
AREDS2 supplements are not a treatment for vision loss that has already occurred. They work as a preventive measure, lowering the odds that moderate disease will advance to the stage where significant vision loss happens. If you’ve been diagnosed with AMD, it’s worth confirming with your eye doctor whether this formula is appropriate for your stage of the disease.
Risk Factors You Can and Can’t Control
Genetics play a major role. Two gene variants in particular, one in the complement factor H gene and another in a region called ARMS2, are strongly associated with AMD risk. Carrying these variants roughly triples the odds of developing late-stage disease compared to people without them. You can’t change your genes, but knowing your family history helps you and your doctor decide how frequently to monitor your eyes.
Smoking is the most significant modifiable risk factor. Current smokers face about four times the risk of developing late AMD compared to people who have never smoked. Quitting at any point reduces future risk. Beyond smoking, a diet rich in leafy greens and fish, regular exercise, and maintaining healthy blood pressure all appear to offer some protective benefit, though none of these lifestyle choices can guarantee prevention.
Monitoring for Changes at Home
If you have dry AMD, one of the most important things you can do is watch for signs that the disease is converting to the wet form, which requires prompt treatment. An Amsler grid, a simple card with a pattern of straight lines and a central dot, is the standard home monitoring tool. You hold it at reading distance, cover one eye, and focus on the center dot. If the surrounding lines appear wavy, broken, or blurred, or if any area looks distorted or discolored, that may signal new blood vessel growth beneath the retina.
The Amsler grid has real limitations. When patients use it on their own, it catches new abnormal vessel growth only about 42 percent of the time. That rate rises modestly to around 53 percent when administered by a professional. It’s a useful early warning system, not a reliable diagnostic tool. Regular eye exams with imaging remain essential for catching changes the grid might miss.
What Experimental Therapies Are Pursuing
Two areas of research are attempting to move beyond disease management toward something closer to a cure. Gene therapy trials are testing whether a one-time injection can deliver genetic instructions that cause the eye to produce its own anti-VEGF protein continuously, potentially eliminating the need for repeated injections in wet AMD. Several of these trials are currently enrolling patients.
Stem cell therapy is taking a different approach, aiming to replace the retinal cells that AMD destroys. In an early-phase trial at the NIH, researchers created tiny patches containing roughly 75,000 retinal pigment cells grown from a patient’s own stem cells, then surgically placed these patches beneath the retina. This work is still in the earliest stages of testing for safety, and it will be years before results clarify whether the approach can meaningfully restore vision.
Neither gene therapy nor stem cell treatment is available outside of clinical trials. They represent plausible paths toward transforming how AMD is treated, but calling them imminent cures would be premature.